ArticleThe Journal of clinical investigation2002
Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis.
Article in The Journal of clinical investigation, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 180 citations in OpenAlex.
- Prenatal alcohol exposure increases the aggressiveness of estrogen-induced pituitary tumors in male rats.Alcohol, clinical & experimental research · 2025Article
- Pituitary somatolactotropes evade an oncogenic response to Ras.Molecular and cellular endocrinology · 2018Article
- The role ofActa medica Lituanic · 2017Article
- Animal models of pituitary neoplasia.Molecular and cellular endocrinology · 2016Review
- Human Pituitary Adenoma Proteomics: New Progresses and Perspectives.Frontiers in endocrinology · 2016Review
- DFG-out mode of inhibition by an irreversible type-1 inhibitor capable of overcoming gate-keeper mutations in FGF receptors.ACS chemical biology · 2015Article
- Pituitary adenomas: historical perspective, surgical management and future directions.CNS oncology · 2015Review
- Persistent ERK/MAPK activation promotes lactotrope differentiation and diminishes tumorigenic phenotype.Molecular endocrinology (Baltimore, Md.) · 2014Article
- Genomic approaches to problems in pituitary neoplasia.Endocrine pathology · 2014Review
- Epidemiology and etiopathogenesis of pituitary adenomas.Journal of neuro-oncology · 2014Review
- FGFR4 polymorphic variants modulate phenotypic features of Cushing disease.Molecular endocrinology (Baltimore, Md.) · 2014Article
- Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer.Cell death & disease · 2014Article
- The role of genetic and epigenetic changes in pituitary tumorigenesis.Neurologia medico-chirurgica · 2014Review
- Is fibroblast growth factor receptor 4 a suitable target of cancer therapy?Current pharmaceutical design · 2014Review
- Genetically engineered mouse models of pituitary tumors.Frontiers in oncology · 2014Review
- Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers.Apoptosis : an international journal on programmed cell death · 2013Review
- The role of mediators of cell invasiveness, motility, and migration in the pathogenesis of silent corticotroph adenomas.Endocrine pathology · 2013Article
- Deficiency of metabolic regulator FGFR4 delays breast cancer progression through systemic and microenvironmental metabolic alterations.Cancer & metabolism · 2013Article
- The cancer-associated FGFR4-G388R polymorphism enhances pancreatic insulin secretion and modifies the risk of diabetes.Cell metabolism · 2013Article
- A call to ARMS: targeting the PAX3-FOXO1 gene in alveolar rhabdomyosarcoma.Expert opinion on therapeutic targets · 2013Review
Corrections and comments
- Retraction · 2015-08-03Concerns/Issues about Data · Criminal Proceedings · Duplication of/in Image · Investigation by Company/Institution · Manipulation of Images · Misconduct - Official Investigation(s) and/or Finding(s) · Objections by Author(s) · · Investigation for Shereen Ezzat and Sylia Asa; JME 06/27/2017
- Commented on by
- Retracted
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is estimated that up to one in five individuals develop pituitary gland tumors. Despite the common occurrence of these tumors, the pathogenetic mechanisms underlying their development remain largely unknown. We report the identification of a novel pituitary tumor-derived, N-terminally truncated isoform of FGF receptor-4 (ptd-FGFR4). The corresponding mRNA results from alternative transcription initiation and encodes a polypeptide that lacks a signal peptide and the first two extracellular Ig-like domains. ptd-FGFR4 has a distinctive cytoplasmic residence, is constitutively phosphorylated, and is transforming in vitro and in vivo. Here we show that targeted expression of ptd-FGFR4, but not FGFR4, results in pituitary tumors that morphologically recapitulate the human disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.